cemiplimab + odronextamab
Phase 1Active 0 watching 0 views this week๐ค Quiet
32
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed/Refractory Aggressive B-Cell Lymphoma
Conditions
Relapsed/Refractory Aggressive B-Cell Lymphoma
Trial Timeline
Jan 11, 2016 โ May 31, 2026
NCT ID
NCT02651662About cemiplimab + odronextamab
cemiplimab + odronextamab is a phase 1 stage product being developed by Regeneron Pharmaceuticals for Relapsed/Refractory Aggressive B-Cell Lymphoma. The current trial status is active. This product is registered under clinical trial identifier NCT02651662. Target conditions include Relapsed/Refractory Aggressive B-Cell Lymphoma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02651662 | Phase 1 | Active |
Competing Products
20 competing products in Relapsed/Refractory Aggressive B-Cell Lymphoma